|1.||Beckman, Eric J: 3 articles (09/2009 - 07/2008)|
|2.||Sivak, Wesley N: 3 articles (09/2009 - 07/2008)|
|3.||Zhang, Jianying: 3 articles (09/2009 - 07/2008)|
|4.||Petoud, Stéphane: 2 articles (09/2008 - 07/2008)|
|5.||Zamboni, William C: 2 articles (09/2008 - 07/2008)|
|6.||Pollack, Ian F: 2 articles (09/2008 - 07/2008)|
|7.||Anderson, Bradley D: 2 articles (03/2008 - 08/2002)|
|8.||Curran, Dennis P: 2 articles (02/2005 - 07/2002)|
|9.||Burke, Thomas G: 2 articles (10/2004 - 07/2002)|
|10.||Curran, D P: 2 articles (07/2001 - 01/2000)|
|1.||Breast Neoplasms (Breast Cancer)
02/01/2010 - "In conclusion, DB-67 is more effective, compared to DB-91, against human tumor growth in in vitro, in vivo-like and in vivo systems. "
02/01/2010 - "While DB-91 showed limited activities, DB-67 exhibited activities against the growth of in vivo-like histocultured human tumors and s.c. "
02/01/2005 - "Together, our data show that DB-67 exhibits potent cytotoxicity and radiosensitization activity by targeting TOP1 in mammalian cells and has great potential for being developed to treat human cancers."
08/01/2002 - "A method for obtaining clear supersaturated aqueous solutions for parenteral administration of the poorly soluble experimental anti-cancer drug silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin (DB-67) has been developed. "
01/01/2000 - "One of the first-generation silatecans, DB-67, is emerging as a serious candidate for cancer chemotherapy."
09/01/2008 - "DB-67 loaded LDI-glycerol polyurethane foams were found to inhibit cellular proliferation by at least 75% in all the malignant glioma cell lines tested (P<1.0x10(-8)). "
02/01/2005 - "As examined by clonogenic survival assay, DB-67 exhibited potent radiosensitization activity at a concentration 10-fold lower than camptothecin in the human glioma D54-MG and T-98G cells, which harbor wild-type and mutant p53, respectively. "
07/01/2008 - "LDI-glycerol polyurethane implants exhibit controlled release of DB-67 and anti-tumor activity in vitro against malignant gliomas."
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/01/2004 - "The growth inhibition of the non-small-cell lung cancer cell lines A549 and H460 after exposure to DB-67 was evaluated with the MTS assay. "
10/01/2004 - "The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells."
10/01/2004 - "To determine the in vitro drug sensitivity of two non-small-cell lung cancer cell lines after treatment with the novel lipophilic camptothecin derivative, 7- tert-butyldimethylsilyl-10-hydroxycamptothecin (DB-67), to determine if topoisomerase I protein levels decrease after treatment with DB-67, and to assess the duration and extent of topoisomerase I modulation after DB-67 exposure, in order to provide information about drug resistance that may be useful in determining an appropriate dosing schedule for DB-67. "
|2.||lysine diisocyanate-glycerol poly(urea-urethane)
|7.||Type I DNA Topoisomerases (Topoisomerase I)
|1.||Drug Therapy (Chemotherapy)